Overview Request Sample Pages Request Customization Download PDF
You are viewing: Australia Gene Expression Analysis Market analysis

The Australia Gene Expression Analysis Market was valued at $61.3 Million in 2026 and projected to reach to $85.1 Million by 2031, representing a compound annual growth rate of 6.8%. Australia's gene expression analysis market is positioned for steady expansion, driven by increasing healthcare investments in genomic research and precision medicine initiatives.

Australia Gene Expression Analysis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Australia Gene Expression Analysis Market Trends and Insights

  • This 6.8% compound annual growth rate reflects Australia's increasing investment in genomic research infrastructure and precision medicine initiatives.
  • Australia's healthcare sector is leveraging advanced gene expression technologies to enhance diagnostic accuracy and personalized treatment strategies across oncology, infectious disease, and genetic disorder management. The Australian market benefits from strong government support for biotechnology research, world-class academic institutions, and growing adoption of RNA sequencing and qPCR platforms in clinical laboratories.
  • Australia's regulatory environment and emphasis on evidence-based medicine are driving healthcare providers to integrate gene expression analysis into routine clinical workflows.
  • Between 2026 and 2031, Australia is expected to see increased demand from both public and private healthcare systems seeking to improve patient outcomes through molecular diagnostics..

Key Market Statistics

  • CAGR (2026-2031) 6.8% CAGR
  • Market Size, 2026 ~USD 61.3 Million
  • Forecast, 2031 ~USD 85.1 Million
  • Country Australia

Australia Gene Expression Analysis Market Overview

Market Valuation Growth :

Australia's gene expression analysis market is valued at USD 61.3 million in 2026, with projections reaching USD 85.1 million by 2031, representing a robust 6.8% CAGR driven by precision medicine adoption.

Genomic Research Infrastructure :

Australia is significantly investing in genomic research facilities and sequencing centers, particularly through institutions like Garvan Institute and University of Melbourne, accelerating gene expression technology deployment across the nation.

Precision Medicine Integration :

Australian healthcare providers are increasingly integrating gene expression analysis into clinical diagnostics and personalized treatment protocols, supported by government funding and private sector collaboration.

Regulatory Support & Initiatives :

Australia's National Health and Medical Research Council (NHMRC) and Therapeutic Goods Administration (TGA) are fostering innovation in genomic medicine, creating favorable conditions for market expansion and technology adoption.

Australia Gene Expression Analysis Market Dynamics

  • The 6.8% CAGR reflects growing adoption among diagnostic laboratories, research institutions, and clinical centers seeking advanced molecular profiling capabilities.
  • Government support through research funding and regulatory frameworks is strengthening market fundamentals. The forecast period through 2031 will see accelerated integration of gene expression technologies in oncology, infectious disease diagnostics, and personalized medicine applications.
  • Australian healthcare providers are prioritizing genomic literacy and infrastructure development, positioning the country as a regional leader in precision medicine.
  • Collaborations between academic institutions and commercial entities will further drive market growth and technology innovation..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Agilent Technologies, Inc.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • Australia's gene expression analysis market is valued at USD 61.3 million in 2026, expanding to USD 85.1 million by 2031 at a 6.8% CAGR.
      • Australia's strong genomic research infrastructure and government support are key drivers of market expansion in precision medicine.
      • RNA sequencing and qPCR technologies are becoming standard tools in Australia's clinical diagnostic laboratories.
      • Australia's healthcare system's shift toward personalized medicine is accelerating adoption of gene expression analysis across oncology and genetic disorder management.

      Gene Expression Analysis Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment ASSAYS & KITS (Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 7% from 2026 to 2031
      Largest Segment REAGENTS & CONSUMABLES (Offering)
      Market Size Base Year (Billions) ~USD 4.23 (2026)
      Revenue Forecast (Billions) ~USD 5.93 (2031)
      Segments Covered Offering, Type

      Australia Gene Expression Analysis Market Report Segmentation

      2 segment dimensions are covered across the global market.

      By Offering

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Type

      • Assays & Kits
      • Bioinformatics & Data Analysis Services
      • Bioinformatics Solutions
      • Cdna Synthesis Kits
      • Cloud-Based Analysis Platforms
      • Data Analysis Software & Visualization Tools
      • Dna Chips
      • Dna Microarray Scanners
      • Enzymes
      • Gene Expression Analysis
      • Gene Expression Databases
      • Library Preparation Kits
      • Microarray Analysis Services
      • Ngs Instruments
      • Other Assays & Kits
      • Other Gene Expression Services
      • Other Instruments
      • Other Reagents & Consumables
      • Pcr Assays & Kits
      • Pcr Instruments
      • Qpcr Profiling Services
      • Rna Isolation Kits
      • Rna Sequencing Services
      • Software

      AUSTRALIA: GENE EXPRESSION ANALYSIS MARKET, BY END USER, 2024–2031

      Segment20242025202620272028202920302031CAGR (%)
      ACADEMIC & RESEARCH INSTITUTES17.518.1192021.122.423.825.46
      CROS1212.613.414.215.216.217.418.87.1
      HOSPITALS & CLINICAL LABORATORIES16.116.91819.220.622.123.825.77.4
      OTHER END USERS4.24.24.24.24.24.24.34.30.5
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES3031.3333537.139.642.345.46.6
      TOTAL79.883.287.692.798.2104.5111.6119.76.4

      Target Audience

      • Diagnostic Laboratory Operators : Australian pathology and diagnostic labs need market data to evaluate gene expression technology investments, understand competitive positioning, and identify growth opportunities in precision diagnostics.
      • Healthcare System Administrators : Hospital networks and healthcare providers require insights into genomic medicine adoption trends, reimbursement models, and infrastructure requirements to optimize precision medicine programs.
      • Medical Device & IVD Manufacturers : Companies developing gene expression platforms and reagents need Australia-specific market intelligence to guide product development, regulatory strategy, and commercial launch planning.
      • Research & Academic Institutions : Universities and research centers require market data to secure funding, justify infrastructure investments, and align genomic research programs with commercial and clinical applications.
      • Investment & Strategy Consultants : Private equity, venture capital, and management consulting firms need detailed Australian market analysis to evaluate investment opportunities and advise clients on genomic medicine sector positioning.

      Key Companies in the Australia Gene Expression Analysis Market

      CompanyHQOwnershipStrongest segments
      ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanyCustom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions,
      DECODE GENETICSIcelandPrivate CompanyInternal Amgen discovery and target validation programs,External research collaborations and grants,Commercial genomics and analytics services,
      GENOMIC HEALTH INCUnited StatesPrivate CompanyOncotype DX Breast Recurrence Score and related breast assays,Oncotype DX Colon and other solid tumor assays,Emerging decision-support and ancillary genomic services,
      TRANSGENOMIC, INC.United StatesPublic CompanyGenetic analytical and pharmacogenomics research services,Multiplexed ICE COLD-PCR reagents and consumables,Other genomic testing and platform technologies (ICE COLD-PCR, cfDNA, CTC assays),
      UNILABSSwitzerlandPrivate CompanyRoutine & specialised laboratory testing,Medical imaging,Pathology & centres of excellence,
      MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Processing assemblies (PAs) and consumables,Licensing and technology access fees,
      GENERAL ELECTRICUnited StatesPublic CompanyCommercial Engines & Services,Defense & Propulsion Technologies,Aircraft Components and Systems (Avio Aero, Unison, Dowty, Colibrium Additive),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyLife Science segment,Clinical Diagnostics segment,
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (immune response, oncology, sexual and reproductive health),Research PCR and enzymes (qPCR, digital PCR, RT-PCR),
      REVVITYUnited StatesPublic CompanyDiagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life Science Reagents & Assays (BioLegend, Dharmacon, AlphaLISA, etc.),Instruments & Imaging Systems,
      PACBIOUnited StatesPublic CompanyLong-read instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read (Onso platform and reagents),
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems,
      EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma Services,
      STANDARD BIOTOOLSUnited StatesPublic CompanyProteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and related systems),Services, software, and other,
      OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyMinION and portable platforms (incl. Mk 1D),GridION / GridION Q benchtop systems,PromethION (P2, P24, P48) high-throughput,
      GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
      TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,PCR instruments and cellular analysis devices,In vitro diagnostics (including COVID-19 testing),

      ATS AUTOMATION TOOLING SYSTEMS INC

      ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.

      DECODE GENETICS

      Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company operates in the genetics and genomics sector.

      GENOMIC HEALTH INC

      Genomic Health Inc. is a private United States company founded in 2000 with 829 employees. The company focuses on genomic testing and personalized medicine.

      TRANSGENOMIC, INC.

      Transgenomic, Inc. is a public United States company founded in 1997 with 19 employees. The company operates in the genomics and molecular diagnostics field.

      UNILABS

      Unilabs is a private Swiss company founded in 1987 with 1,897 employees. The company provides laboratory and diagnostic services.

      MAXCYTE, INC

      MaxCyte, Inc. is a public United States company founded in 1998 with 91 employees. The company develops cell engineering technologies.

      GENERAL ELECTRIC

      General Electric is a public United States company founded in 1892 with 57,000 employees. The company operates across multiple industrial and technology sectors.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a public United States company founded in 1956 with 125,000 employees. The company is a global leader in life sciences, analytical instruments, and laboratory services.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public United States company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.

      ILLUMINA, INC.

      Illumina, Inc. is a public United States company founded in 1998 with 8,625 employees. The company is a leading provider of DNA sequencing and genetic analysis technologies.

      QIAGEN

      QIAGEN is a public company founded in 1984 in the Netherlands with 5,500 employees. The company develops and manufactures molecular diagnostics and life sciences products.

      REVVITY

      Revvity is a public United States company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for research and diagnostics.

      PACBIO

      PacBio is a public United States company founded in 2000 with 485 employees. The company develops long-read DNA sequencing technologies.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a public United States company founded in 1999 with 18,000 employees. The company manufactures analytical instruments, software, and services for life sciences and diagnostics.

      SYSMEX CORPORATION

      Sysmex Corporation is a public Japanese company founded in 1968 with 10,861 employees. The company manufactures and sells in vitro diagnostic systems and laboratory instruments.

      EUROFINS SCIENTIFIC

      Eurofins Scientific is a public company founded in 1987 in Luxembourg with 65,694 employees. The company is a leading provider of laboratory testing and analytical services globally.

      STANDARD BIOTOOLS

      Standard Biotools is a public United States company founded in 1999 with 387 employees. The company develops microfluidics and cell analysis technologies.

      OXFORD NANOPORE TECHNOLOGIES PLC

      Oxford Nanopore Technologies PLC is a public United Kingdom company founded in 2005 with 1,316 employees. The company develops nanopore-based DNA and RNA sequencing technologies.

      GENSCRIPT

      GenScript is a public company founded in 2002 in Hong Kong with 6,165 employees. The company provides biotechnology research services and products including gene synthesis and protein production.

      TAKARA BIO INC.

      Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. The company manufactures and sells molecular biology reagents and research products.

      Reasons to Buy this Report

      • Market-Specific Growth Projections : Access detailed forecasts for Australia's gene expression market through 2031, enabling strategic planning aligned with regional growth trajectories and investment opportunities in precision medicine infrastructure.
      • Competitive Landscape Intelligence : Understand key players, market consolidation trends, and competitive positioning specific to Australia's genomic diagnostics sector, informing market entry and partnership strategies.
      • Regulatory & Reimbursement Insights : Gain clarity on Australian TGA approvals, NHMRC funding mechanisms, and Medicare reimbursement pathways for gene expression tests, critical for commercialization planning.
      • End-User Adoption Patterns : Identify adoption rates across Australian hospitals, pathology labs, and research institutions, revealing market penetration opportunities and customer acquisition strategies by segment.
      • Regional Investment Opportunities : Discover high-growth segments within Australia's market, including oncology diagnostics, infectious disease testing, and personalized medicine applications with strongest ROI potential.

      Frequently asked questions

      What is the current size of Australia's gene expression analysis market?

      Australia's gene expression analysis market is valued at USD 61.3 million in 2026 and is projected to reach USD 85.1 million by 2031.

      What is the expected growth rate for Australia's gene expression analysis market?

      Australia's gene expression analysis market is expected to grow at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2031.

      Which technologies are driving growth in Australia's gene expression analysis market?

      RNA sequencing, quantitative PCR (qPCR), and microarray technologies are the primary drivers of growth in Australia's gene expression analysis market.

      What factors are contributing to market expansion in Australia?

      Australia's market growth is driven by government support for biotechnology research, increasing adoption of precision medicine, and growing demand from clinical laboratories for molecular diagnostics.

      Which healthcare segments are adopting gene expression analysis in Australia?

      Oncology, infectious disease management, and genetic disorder diagnosis are the primary healthcare segments adopting gene expression analysis in Australia.

      RESEARCH METHODOLOGY

      This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global gene expression analysis market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the gene expression analysis market. The secondary sources used for this study include World Health Organization (WHO), Food and Drug Administration (FDA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Environmental Protection Agency (EPA), European Medicines Agency (EMA), Biotechnology Innovation Organization (BIO), International Society for Pharmaceutical Engineering (ISPE), National Institute for Health and Care Excellence (NICE), World National Center for Biotechnology Information (NCBI), International Trade Centre, Journal of Molecular Biology, Journal of Biological Chemistry (JBC), American Association for Cancer Research (AACR), the American Society of Human Genetics (ASHG), and the European Molecular Biology Organization (EMBO). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, among others.

      Secondary data were collected and analyzed to determine the overall size of the global gene expression analysis market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Gene Expression Analysis Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the gene expression analysis market. These methods were also used extensively to estimate the size of various market segments.

      Gene Expression Analysis Market : Top-Down and Bottom-Up Approach

      Gene Expression Analysis Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Gene expression analysis is the systematic investigation of the activity levels of genes within a cell, tissue, or organism at a specific point in time, which involves measuring & quantifying the production of RNA or protein molecules encoded by genes that reflect the degree to which genes are being transcribed and translated into functional products. In gene expression analysis, we use products & services related to the analysis and measurement of gene expression. This market includes gene expression analysis products & services such as reagents & consumables, instruments, gene expression analysis services, and bioinformatics solutions.

      Key Stakeholders

      • Pharmaceutical & biotechnology companies
      • Contract research organizations (CROs)
      • Life science companies
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the gene expression analysis market based on offering, application, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall gene expression analysis market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the gene expression analysis market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the gene expression analysis market
      • To benchmark players within the gene expression analysis market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Customization Options

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Geographical Analysis

      • Further breakdown of the Rest of Europe gene expression analysis market, by country
      • Further breakdown of the Rest of Asia Pacific gene expression analysis market, by country
      • Further breakdown of the Rest of Latin America gene expression analysis market, by country
      • Further breakdown of the Rest of Middle East gene expression analysis market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Gene Expression Analysis Market Report

      Full forecast, segment splits, and company analysis for all Gene Expression Analysis Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status